From Wikipedia, the free encyclopedia
Chemical compound
Namodenoson
![](https://upload.wikimedia.org/wikipedia/commons/thumb/d/dc/Namodenoson.svg/220px-Namodenoson.svg.png) |
|
Other names | Chloro-IB-MECA; 2-Cl-IB-MECA |
---|
|
Legal status |
|
---|
|
(2S,3S,4R,5R)-5-[2-Chloro-6-[(3-iodophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide
|
CAS Number | |
---|
PubChem
CID | |
---|
IUPHAR/BPS | |
---|
DrugBank | |
---|
ChemSpider | |
---|
UNII | |
---|
KEGG | |
---|
ChEMBL | |
---|
CompTox Dashboard (
EPA) | |
---|
ECHA InfoCard |
100.162.091
![Edit this at Wikidata](https://upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/10px-OOjs_UI_icon_edit-ltr-progressive.svg.png) |
---|
|
Formula | C18H18ClIN6O4 |
---|
Molar mass | 544.73 g·mol−1 |
---|
3D model (
JSmol) | |
---|
CNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=C(N=C32)Cl)NCC4=CC(=CC=C4)I)O)O
|
InChI=1S/C18H18ClIN6O4/c1-21-16(29)13-11(27)12(28)17(30-13)26-7-23-10-14(24-18(19)25-15(10)26)22-6-8-3-2-4-9(20)5-8/h2-5,7,11-13,17,27-28H,6H2,1H3,(H,21,29)(H,22,24,25)/t11-,12+,13-,17+/m0/s1 Key:IPSYPUKKXMNCNQ-PFHKOEEOSA-N
|
Namodenoson is a small molecule A3
adenosine receptor (A3AR) agonist. It is developed by Can-Fite for
non-alcoholic fatty liver disease,
[1] liver cancer,
[2] and pancreatic cancer.
[3]
-
^ Safadi, Rifaat; Braun, Marius; Francis, Adi; Milgrom, Yael; Massarwa, Muhammad; Hakimian, David; Hazou, Wadi; Issachar, Assaf; Harpaz, Zivit; Farbstein, Motti; Itzhak, Inbal; Lev-Cohain, Naama; Bareket-Samish, Avital; Silverman, Michael H.; Fishman, Pnina (December 2021).
"Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis". Alimentary Pharmacology & Therapeutics. 54 (11–12): 1405–1415.
doi:
10.1111/apt.16664.
ISSN
1365-2036.
PMC
9298378.
PMID
34671996.
-
^ Stemmer, Salomon M.; Manojlovic, Nebojsa S.; Marinca, Mihai Vasile; Petrov, Petar; Cherciu, Nelly; Ganea, Doina; Ciuleanu, Tudor Eliade; Pusca, Ioana Adriana; Beg, Muhammad Shaalan; Purcell, William T.; Croitoru, Adina-Emilia; Ilieva, Rumyana Nedyalkova; Natošević, Sladjana; Nita, Amedeia Lavinir; Kalev, Dimitar Nikolaev; Harpaz, Zivit; Farbstein, Motti; Silverman, Michael H.; Bristol, David; Itzhak, Inbal; Fishman, Pnina (7 January 2021).
"Namodenoson in Advanced Hepatocellular Carcinoma and Child–Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial". Cancers. 13 (2): 187.
doi:
10.3390/cancers13020187.
ISSN
2072-6694.
PMC
7825785.
PMID
33430312.
-
^ Fishman, Pnina; Bareket-Samish, Avital; Itzhak, Inbal (1 June 2023). "Effects of namodenoson on pancreatic carcinoma: Preclinical evidence". Journal of Clinical Oncology. 41 (16_suppl): e15134.
doi:
10.1200/JCO.2023.41.16_suppl.e15134.
S2CID
259081369.